Abstract
Background
Hypertension (HTN) is a major risk factor for Alzheimer's disease (AD) and related dementias. Renin-angiotensin system (RAS) medications, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been proposed to mitigate cognitive decline, but evidence remains inconsistent.
Objective
Compare global cognition over time among ARB, ACEI, and non-RAS drug users.
Methods
Data from the Rush Memory and Aging Project (1997–2006) included 2019 participants. Global cognition was assessed using a composite z-score of 19 cognitive tests. Participants were categorized by medication use: ARB, ACEI, or non-RAS. Analysis of covariance (ANCOVA) was performed to compare cognitive outcomes over 9 years, adjusting for baseline cognition, social determinants, and medical factors. Subgroup analyses evaluated cognitive domains and the impact of HTN.
Results
At baseline, ARB and ACEI users had more vascular risk factors and medical conditions than non-RAS users. At 9 years, ARB users had slightly better global cognitive outcomes compared to ACEI (LS-mean difference: 0.015, 95% CI [−0.175, 0.205]) and non-RAS users (LS-mean difference: 0.06, 95% CI [−0.11, 0.23]), though differences were not statistically significant. ACEI users showed significant improvement in working memory compared to non-RAS users (LS-mean: 0.157, 95% CI [0.002, 0.313]). Among participants without HTN, ACEI use was associated with significantly reduced cognitive decline compared to non-RAS use.
Conclusions
ARBs may benefit global cognitive function, while ACEIs may yield improvements in specific domains like working memory. Further studies are needed to confirm these findings and explore the impact of drug characteristics such as blood-brain-barrier penetration.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
